CytoSorbents Expects Upside FY21 Sales, Despite COVID-19 Headwinds

CytoSorbents Corp CTSO reported preliminary Q4 FY21 revenue of approximately $10.8 million, better than the consensus of $9.58 million. It reported revenue of $12.0 million in Q4 2020.

  • The company expects blended product gross margins to be approximately 80% for Q4 FY21, mixing higher margin direct and lower margin distributor and partner sales.
  • In its stockholder letter, CytoSorbents detailed it had a good 2021 with total revenue of $43.2 million (vs. the consensus of $41.95 million) and product sales of $40.1 million, both slightly ahead of results in 2020, despite headwinds from the COVID-19 pandemic. 
  • Cumulative CytoSorb treatments delivered exceeded 162,000, up 34% from approximately 121,000 at the end of 2020.
  • The company held a cash balance at the end of 2021 of approximately $54 million.
  • In Q1 2022, CytoSorbents plan to renew a $15 million term loan agreement with Bridge Bank, ensuring continued financial flexibility.
  • Price Action: CTSO shares are up 4.04% at $3.35 during the market session on the last check Tuesday.
Loading...
Loading...
CTSO Logo
CTSOCytoSorbents Corp
$0.82901.01%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
37.41
Growth
18.40
Quality
Not Available
Value
63.25
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Comments
Loading...